CytomX Therapeutics, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that CytomX Therapeutics, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $76.20M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $138.10M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $101.21M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $53.16M | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | $37.31M | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | $68.43M | Mar 27, 2023 |
| FY2021 | Dec 31, 2019 | $26.90M | Mar 27, 2023 |
| FY2018 | Dec 31, 2018 | $11.47M | Feb 27, 2019 |
| FY2017 | Dec 31, 2017 | $27.07M | Mar 7, 2018 |
| FY2017 | Sep 30, 2017 | $24.14M | Mar 7, 2018 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $76.20M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $138.10M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $101.21M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $53.16M | Mar 11, 2024 |
| FY2022 | Sep 30, 2022 | $11.15M | Mar 27, 2023 |
| FY2022 | Jun 30, 2022 | $12.85M | Mar 27, 2023 |
| FY2022 | Mar 31, 2022 | $9.04M | Mar 27, 2023 |
| FY2021 | Dec 31, 2021 | $11.13M | Mar 27, 2023 |
| FY2021 | Sep 30, 2021 | $9.19M | Mar 27, 2023 |
| FY2021 | Jun 30, 2021 | $8.80M | Mar 27, 2023 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($17.37M) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $31.87M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | ($569.0K) | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | ($99.32M) | Mar 11, 2024 |
| FY2022 | Sep 30, 2022 | ($29.06M) | Mar 27, 2023 |
| FY2022 | Jun 30, 2022 | ($29.50M) | Mar 27, 2023 |
| FY2022 | Mar 31, 2022 | ($31.98M) | Mar 27, 2023 |
| FY2021 | Dec 31, 2021 | ($34.82M) | Mar 27, 2023 |
| FY2021 | Sep 30, 2021 | ($30.98M) | Mar 27, 2023 |
| FY2021 | Jun 30, 2021 | ($26.74M) | Mar 27, 2023 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($22.36M) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $25.00M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | ($6.48M) | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | ($101.34M) | Mar 11, 2024 |
| FY2022 | Sep 30, 2022 | ($29.71M) | Mar 27, 2023 |
| FY2022 | Jun 30, 2022 | ($30.05M) | Mar 27, 2023 |
| FY2022 | Mar 31, 2022 | ($32.06M) | Mar 27, 2023 |
| FY2021 | Dec 31, 2021 | ($34.90M) | Mar 27, 2023 |
| FY2021 | Sep 30, 2021 | ($31.04M) | Mar 27, 2023 |
| FY2021 | Jun 30, 2021 | ($26.70M) | Mar 27, 2023 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $68.73M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $83.38M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $77.68M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $111.65M | Mar 11, 2024 |
| FY2022 | Sep 30, 2022 | $30.37M | Mar 27, 2023 |
| FY2022 | Jun 30, 2022 | $31.16M | Mar 27, 2023 |
| FY2022 | Mar 31, 2022 | $30.56M | Mar 27, 2023 |
| FY2021 | Dec 31, 2021 | $36.58M | Mar 27, 2023 |
| FY2021 | Sep 30, 2021 | $29.14M | Mar 27, 2023 |
| FY2021 | Jun 30, 2021 | $26.10M | Mar 27, 2023 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($75.59M) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | ($86.23M) | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | ($56.04M) | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | ($110.79M) | Mar 11, 2024 |
| FY2022 | Sep 30, 2022 | ($109.39M) | Mar 27, 2023 |
| FY2022 | Jun 30, 2022 | ($75.55M) | Mar 27, 2023 |
| FY2022 | Mar 31, 2022 | ($41.31M) | Mar 27, 2023 |
| FY2022 | Dec 31, 2021 | ($119.03M) | Mar 27, 2023 |
| FY2021 | Sep 30, 2021 | ($87.84M) | Mar 27, 2023 |
| FY2021 | Jun 30, 2021 | ($58.14M) | Mar 27, 2023 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $220.0K | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $310.0K | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $840.0K | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $1.74M | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | $1.61M | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | $2.31M | Mar 27, 2023 |
| FY2021 | Dec 31, 2019 | $3.50M | Mar 27, 2023 |
| FY2020 | Dec 31, 2018 | $3.79M | Feb 24, 2021 |
| FY2019 | Dec 31, 2017 | $1.56M | Feb 27, 2020 |
| FY2018 | Dec 31, 2016 | $2.18M | Feb 27, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $151.57M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $120.53M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $201.79M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $260.89M | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | $339.41M | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | $358.66M | Mar 27, 2023 |
| FY2020 | Dec 31, 2019 | $341.28M | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | $457.11M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $397.64M | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | $199.13M | Mar 7, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $52.56M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $120.99M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $249.24M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $346.64M | Mar 11, 2024 |
| FY2022 | Sep 30, 2022 | $307.03M | Mar 27, 2023 |
| FY2022 | Jun 30, 2022 | $314.62M | Mar 27, 2023 |
| FY2022 | Mar 31, 2022 | $326.56M | Mar 27, 2023 |
| FY2022 | Dec 31, 2021 | $339.87M | Mar 27, 2023 |
| FY2021 | Sep 30, 2021 | $340.80M | Mar 27, 2023 |
| FY2021 | Jun 30, 2021 | $344.33M | Mar 27, 2023 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $99.01M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | ($456.0K) | Mar 16, 2026 |
| FY2025 | Dec 31, 2023 | ($47.45M) | Mar 16, 2026 |
| FY2024 | Dec 31, 2022 | ($85.75M) | Mar 6, 2025 |
| FY2022 | Sep 30, 2022 | ($80.54M) | Mar 27, 2023 |
| FY2022 | Jun 30, 2022 | ($54.54M) | Mar 27, 2023 |
| FY2022 | Mar 31, 2022 | ($29.74M) | Mar 27, 2023 |
| FY2023 | Dec 31, 2021 | ($459.0K) | Mar 11, 2024 |
| FY2021 | Sep 30, 2021 | $30.43M | Mar 27, 2023 |
| FY2021 | Jun 30, 2021 | $58.11M | Mar 27, 2023 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $949.0K | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $949.0K | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $949.0K | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $949.0K | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | $949.0K | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | $949.0K | Mar 27, 2023 |
| FY2020 | Dec 31, 2019 | $949.0K | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | $949.0K | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $949.0K | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | $949.0K | Mar 7, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($711.95M) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | ($691.58M) | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | ($723.45M) | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | ($722.88M) | Mar 11, 2024 |
| FY2022 | Sep 30, 2022 | ($714.10M) | Mar 27, 2023 |
| FY2022 | Jun 30, 2022 | ($685.04M) | Mar 27, 2023 |
| FY2022 | Mar 31, 2022 | ($655.54M) | Mar 27, 2023 |
| FY2022 | Dec 31, 2021 | ($623.56M) | Mar 27, 2023 |
| FY2021 | Sep 30, 2021 | ($588.74M) | Mar 27, 2023 |
| FY2021 | Jun 30, 2021 | ($557.76M) | Mar 27, 2023 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $12.67M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $38.05M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $17.17M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | $193.65M | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | $205.53M | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | $191.86M | Mar 27, 2023 |
| FY2021 | Dec 31, 2019 | $188.43M | Mar 27, 2023 |
| FY2019 | Dec 31, 2018 | $247.58M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | $177.55M | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | $104.65M | Mar 7, 2018 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 170.19M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | 80.10M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | 67.31M | Mar 6, 2025 |
| FY2023 | Dec 31, 2022 | 66.23M | Mar 11, 2024 |
| FY2022 | Dec 31, 2021 | 65.39M | Mar 27, 2023 |
| FY2021 | Dec 31, 2020 | 48.25M | Mar 27, 2023 |
| FY2020 | Dec 31, 2019 | 45.52M | Feb 24, 2021 |
| FY2019 | Dec 31, 2018 | 45.08M | Feb 27, 2020 |
| FY2018 | Dec 31, 2017 | 38.48M | Feb 27, 2019 |
| FY2017 | Dec 31, 2016 | 36.49M | Mar 7, 2018 |